RSS-Feed abonnieren
PDF herunterladen
DOI: 10.4103/ijmpo.ijmpo_260_20
Venetoclax – The Game-changer in Hematology
Autoren
Financial support and sponsorship Nil.
Abstract
The introduction of small molecule inhibitors in many hematological malignancies made a landmark achievement in this field with a dramatic change in the survival outcome. Venetoclax is a B-cell lymphoma-2 inhibitor which has become the game-changer molecule in chronic lymphocytic leukemia and acute myeloid leukemia. This review is intended to summarize the mechanism of action, side effects, dosage, and different phases of clinical trials of this drug with review of literature.
Keywords
Acute myeloid leukemia - B-cell lymphoma-2 inhibitor - chronic lymphocytic leukemia - venetoclaxPublikationsverlauf
Eingereicht: 26. Mai 2020
Angenommen: 11. August 2020
Artikel online veröffentlicht:
17. Mai 2021
© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941-53
- 2 Martens U. Small Molecules in Hematology. USA: Springer Nature; 2018
- 3 Brody T. FDA's Drug Review Process and the Package Label: Strategies for Writing Successful FDA Submissions. United Kingdom: Academic Press, Elsevier Science Publishing Co.; 2017
- 4 Scheffold A, Jebaraj BMC, Stilgenbauer S. Venetoclax: Targeting BCL2 in Hematological Cancers. Recent Results Cancer Res 2018; 212: 215-42
- 5 Lenz G, Salles G. Aggressive Lymphomas. USA: Springer International Publishing; 2018
- 6 Fairbrother WJ, Leverson JD, Sampath D, Souers AJ. Discovery and Development of Venetoclax, a Selective Antagonist of BCL-2. Successful Drug Discovery. edited by János Fischer. et al 1st ed. Wiley; 2019: 225-45 DOI.org (Crossref),
- 7 Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J. et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood 2016; 127: 3215-24
- 8 Ackler S, Oleksijew A, Chen J, Chyla BJ, Clarin J, Foster K. et al. Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax. Pharmacol Res Perspect 2015; 3: e00178
- 9 Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF. et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2016; 374: 311-22
- 10 Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G. et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med 2019; 380: 2095-103
- 11 Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S. et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018; 378: 1107-20
- 12 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy - Full Text View - ClinicalTrials. Gov.. https://clinicaltrials.gov/ct2/show/NCT02993523 Available from: [Last accessed 2020 Aug 20]
- 13 Davids MS, Chatterjee A, Ravelo A, Shapouri S, Manzoor BS, Sail K. et al. Cost-effectiveness of a 12-month fixed duration of venetoclax in combination with obinutuzumab in first-line chronic lymphocytic Leukemia in the United States. Blood 2019; 134 Suppl 1: 4741
- 14 Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP. et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica 2019; 104: e68-e71
- 15 Morschhauser F, Feugier P, Flinn IW, Gasiorowski RE, Greil R, Illés Á. Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma (DLBCL):First safety, efficacy and biomarker analyses from the phase II CAVALLI study. Blood. 2018; 132: 782 et al. (supplement 1)
- 16 Zinzani PL, Flinn IW, Yuen S, Topp MS, Rusconi C, Fleury I. Efficacy and safety of venetoclax (Ven) + rituximab ® or Ven + Bendamustine (B) + R randomized versus B + R in Patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Final analysis of phase II CONTRALTO study. Blood 2018; 132: 1614 et al. Suppl 1
- 17 Wong KY, Chim CS. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma. J Pharm Pharmacol 2020; 72: 728-37